BioCentury
ARTICLE | Clinical News

Lixivaptan regulatory update

March 19, 2012 7:00 AM UTC

FDA accepted for review an NDA from Cornerstone for lixivaptan to treat hyponatremia. The PDUFA date is Oct. 29. Cornerstone gained the selective vasopressin V2 receptor antagonist through its Januar...